– USA, MA – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Catherine Stehman-Breen, M.D., to its Board of Directors.
“Catherine has played an instrumental role in Dyne’s launch and product strategy and in establishing relationships with the patient communities that we strive to serve,” said Jason P. Rhodes, Dyne executive chairman and partner at Atlas Venture. “We are fortunate to have her joining the Board as we pursue our mission of developing life-transforming therapies.”
About Dr. Stehman-Breen
Dr. Stehman-Breen is currently an independent board member at Generation Bio and is an entrepreneur-in-residence with Atlas Venture. She previously served as chief medical officer of Sarepta Therapeutics, a biopharmaceutical company focused on RNA-targeted therapeutics, as vice president, clinical development at Regeneron Pharmaceuticals, and held senior leadership positions at Amgen, including as vice president, global development, where she led several therapeutic areas.
“This is an exciting time at Dyne as we advance our platform of targeted therapies for patients with serious muscle diseases, including DM1 and DMD,” said Stehman-Breen. “I look forward to working closely with the Board and leadership team as we build on the company’s progress to date including Dyne’s support of END-DM1, a natural history study to advance the understanding of DM1 disease progression.”
About Dyne Therapeutics
Dyne Therapeutics is pioneering therapies that target muscle tissue with unprecedented precision to restore muscle health. The company’s FORCE platform delivers oligonucleotides and other molecules to the skeletal, cardiac and smooth muscle to treat a range of serious muscle diseases. Dyne is advancing treatment for myotonic dystrophy type 1 in addition to programs for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy. Dyne launched in 2019 and is based in Cambridge, Mass.
For more information: https://www.dyne-tx.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.